Contract Manufacturer Posts Sharp Revenue Jump Ahead of Rs 24.77 Crore Fundraise; Sustainability Questions Emerge
ANL operates as a Contract Development and Manufacturing Organization (CDMO) specializing in Ayurvedic and Nutraceutical products across multiple dosage forms. Established in 2021, the company manufactures tablets (film-coated and chewable), capsules (hard gelatine and HPMC), oral liquids (syrups, suspensions, tonics), traditional Ayurvedic powders (churans), medicated oils, and external preparations including balms, ointments, creams, and gels.
The product applications span liver care, gynaecological care, bone and joint health, respiratory support, digestive health, pain relief, skin care, and hair care. ANL serves both domestic and international markets, including Sri Lanka, Singapore, and the USA.
Revenue Structure and Geographic Concentration
The business operates through two verticals with notably skewed contribution:
Domestic Sales & Merchant Exports: 96.62% of revenue (FY25) and 99.21% (H1-FY26) – conducted on a loan license basis Direct Exports: 3.38% of revenue (FY25) declining to 0.79% (H1-FY26)
Geographically, a significant majority of revenue is generated within Gujarat state, indicating high regional concentration. The company operates with just 18 employees on payroll as of the offer document date, supplemented by contract labor as needed.
Strategic Priorities
ANL’s stated focus areas include:
- Strengthening sales and marketing networks
- Enhancing global presence through direct exports and international product registrations
- Expanding and differentiating the product portfolio
- Leveraging existing customer relationships
The Financial Trajectory: A Pre-IPO Acceleration
ANL’s financial performance shows dramatic growth, particularly in the pre-IPO period:
Revenue Pattern: Rs 3.07 crore (FY23) → Rs 5.20 crore (FY24) → Rs 16.06 crore (FY25). For H1-FY26, total income reached Rs 14.07 crore, suggesting annualized revenue around Rs 28 crore.
Profit Growth: Net profit grew from Rs 0.28 crore (FY23) to Rs 0.82 crore (FY24) to Rs 2.61 crore (FY25). H1-FY26 delivered Rs 2.33 crore profit.
The numbers reveal a 209% revenue jump from FY24 to FY25, with FY25 alone accounting for more revenue than the previous two years combined. This sharp acceleration immediately preceding the IPO timeline raises questions about the underlying business momentum and sustainability of such growth rates.
Margin and Return Metrics
PAT Margins: 9.67% (FY23) → 16.42% (FY24) → 16.33% (FY25) → 16.59% (H1-FY26)
RoCE: 12.51% (FY23) → 28.98% (FY24) → 36.98% (FY25) → 49.09% (H1-FY26)
Average RoNW: 67.45% over the last three fiscals
The company achieved an average EPS of Rs 4.49 over three fiscals. The RoCE progression from 12.51% to 49.09% and RoNW averaging 67.45% represent exceptionally high returns, particularly for a contract manufacturing business in a competitive segment established only in 2021.
Debt Position
As of September 30, 2025, ANL carried debt of Rs 4.43 crore—a notable leverage position for a company with net worth of Rs 8.90 crore (implied from NAV of Rs 16.74 on 5.32 crore shares), representing a debt-to-equity ratio approaching 0.5x.
The Issue at a Glance
Accretion Nutraveda Ltd. (ANL) is set to debut on the BSE SME platform with a book-building IPO opening January 28, 2026. The Gujarat-based contract manufacturer of Ayurvedic and Nutraceutical products is offering 1.92 million equity shares in a price band of Rs 122-129, targeting Rs 24.77 crore at the upper end. The three-day subscription window closes January 30, with a minimum application size of 2,000 shares.
Valuation Analysis
At the upper price band of Rs 129 per share:
- P/E of 35.73 based on FY25 earnings
- P/E of 20.03 based on FY26 annualized projections (from H1 data)
- P/BV of 7.71 against pre-IPO NAV of Rs 16.74 (Sept 30, 2025)
- P/BV of 2.68 against post-IPO NAV of Rs 48.20 per share
The dramatic difference between pre-IPO and post-IPO price-to-book ratios reflects the significant dilution impact on a small equity base.
Issue Structure and Use of Proceeds
The Rs 24.77 crore issue (at upper cap) is entirely a fresh issue of 1.92 million shares, constituting 26.52% of post-IPO equity.
Proceeds Allocation:
- Rs 8.03 crore: Machinery for new manufacturing setup
- Rs 4.22 crore: Machinery for automation
- Rs 5.50 crore: Working capital
- Balance: General corporate purposes
Post-IPO, paid-up capital expands from Rs 5.32 crore to just Rs 7.24 crore, with targeted market cap of Rs 93.40 crore.
Small Equity Base Implications
The post-IPO equity capital of Rs 7.24 crore represents a notably small base. For context, migration from SME to main board typically requires meeting minimum public shareholding and market cap thresholds. The small equity base suggests a longer gestation period before any potential main board migration, limiting liquidity runway for investors.
Promoters’ average acquisition cost ranges from Rs 5.67 to Rs 6.23 per share. The company issued shares at Rs 130 between March 2025 and September 2025, and executed a 9:1 bonus issue in September 2025. Initial equity shares were issued at par value of Rs 10.
At the IPO price of Rs 129, promoters realize approximately 20x their average acquisition cost—a substantial markup achieved within a short timeframe since the company’s 2021 inception.
Peer Comparison
The offer document lists Walpar Nutritions (P/E 19.3) and Influx Healthcare (P/E 25.5 as of January 21, 2026) as listed peers. However, it notes these are not comparable on an apple-to-apple basis.
ANL’s FY25 P/E of 35.73 sits above both comparables, despite being a younger, smaller-scale operation in the same competitive space.
Dividend Policy
ANL has not declared dividends during the reported periods. The company will adopt a prudent dividend policy based on financial performance and future prospects.
Key Considerations for Investors
Revenue Concentration: With 99%+ revenue from domestic sales and merchant exports (conducted on loan license basis) and significant geographic concentration in Gujarat, the business shows limited diversification.
Pre-IPO Growth Surge: The 209% revenue jump in FY25 and sustained momentum in H1-FY26, immediately preceding the IPO, follows a pattern that warrants examination regarding organic sustainability versus pre-IPO optimization.
Young Operating History: Established in 2021, the company has limited operating history to assess through multiple business cycles or market conditions.
Competitive Landscape: Operating as a CDMO in the Ayurvedic and Nutraceutical space—a highly competitive and fragmented segment—raises questions about sustainable differentiation and pricing power.
Exceptional Returns: RoNW of 67.45% and RoCE reaching 49.09% appear exceptionally high for a contract manufacturing business, suggesting either extraordinary operational efficiency or potentially unsustainable conditions.
Lean Organization: Just 18 permanent employees handling Rs 28+ crore annualized revenue indicates either exceptional productivity or heavy reliance on contract labor and outsourced operations.
Debt Position: Rs 4.43 crore debt on a small equity base represents meaningful leverage that will require management attention alongside growth initiatives.
Valuation Premium: At 35.73x FY25 earnings and 7.71x pre-IPO book value, the pricing embeds significant growth expectations for a young company in a competitive sector.
Migration Timeline: The Rs 7.24 crore post-IPO equity base indicates an extended timeline before potential main board migration becomes feasible.
Capital Deployment: Unlike debt repayment-focused IPOs, proceeds target manufacturing expansion and automation, though working capital allocation of Rs 5.50 crore (22% of gross proceeds) is substantial.
IPO Snapshot: Accretion Nutraveda Ltd.
| Parameter | Details |
|---|---|
| Company Name | Accretion Nutraveda Ltd. (ANL) |
| Issue Type | IPO (Initial Public Offering) – Book Building |
| Platform | BSE SME |
| Issue Size | 1,920,000 equity shares |
| Face Value | Rs 10 per share |
| Price Band | Rs 122 – Rs 129 per share |
| Issue Opens | January 28, 2026 |
| Issue Closes | January 30, 2026 |
| Minimum Lot Size | 2,000 shares |
| Additional Lots | Multiples of 1,000 shares |
| Total Issue Size (Upper Band) | Rs 24.77 crore |
| Fresh Issue | Rs 24.77 crore (100%) |
| Offer for Sale (OFS) | Nil |
| Post-Issue Paid-up Capital | Rs 7.24 crore |
| Post-Issue Market Cap | Rs 93.40 crore |
| Issue as % of Equity | 26.52% |
| Lead Manager | Sobhagya Capital Options Pvt. Ltd. |
| Registrar | KFin Technologies Ltd. |
| Market Maker | Sunflower Broking Pvt. Ltd. |
| Syndicate Member | Investeria Financial Services Ltd. |
| Listing | BSE SME Platform |
| Object of Issue | • New Manufacturing Setup: Rs 8.03 cr • Automation Machinery: Rs 4.22 cr • Working Capital: Rs 5.50 cr • General Corporate Purposes |
| Year of Incorporation | 2021 |
